Since the first World Health Organization notification on 31 December 2019, coronavirus
disease 2019 (COVID‐19), the respiratory disease caused by the coronavirus severe acute …

Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
began when the first sequence was published, and this forms the basis for …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December
2019 1, 2 and is responsible for the coronavirus disease 2019 (COVID-19) pandemic 3. …

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …